LEXINGTON, Mass.-(BUSINESS WIRE)-MC10, Inc., the developer of BioStamp nPoint, an end-to-end system for physiological data collection and analytics, announced today that the BioStamp nPoint system will be utilized to collect and assess movement activity data in a new Phase III study evaluating a potential treatment for chorea associated with Huntington disease, a hereditary neurodegenerative disease.

In a subset of 50 study participants, BioStamp nPoint will track activity, sleep and posture, and investigate exploratory measurements of gait disturbances and truncal chorea, which are involuntary movement symptoms of Huntington disease.

The use of BioStamp nPoint to collect objective measures of Huntington disease represents a potential shift from the currently used subjective measures, including the Unified Huntington Disease Rating Scale and other survey-based assessments.

“We are excited about the continued use of our system in CNS studies, especially in partnership with Neurocrine Biosciences, a leader in advancing the treatment of movement disorders,” said Arthur Combs M.D., Chief Medical Officer of MC10. “Huntington disease impacts various aspects of a person’s life, and the ability to collect objective data on activity, sleep, posture, and involuntary movements on a 24-7 basis promises to provide new context to improve our overall understanding of the disease and associated symptoms and help advance treatment options.”

MC10, BioStamp nPoint, and the MC10 logo are registered marks owned by MC10, Inc..